Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amit Bar-Or

Neurology Philadelphia, PA Medical Doctor

NPI 1528508843 CMS profile 3877536

3400 Spruce St, 2 Ravdin, Philadelphia, PA 19104

Open in the dashboard

General payments

$595,877

347 records reported · program years 2019–2025

Research payments

$150,893

Paid to them · 145 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,134,114 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Amit Bar-Or of Philadelphia, PA is reported in the CMS Open Payments database as having received $595,877 across 347 general payments and $150,893 in research payments paid to them. Separately, studies naming them as principal investigator received $7,134,114 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $70,818 31
2025 Research $26,929 33
2024 General $100,696 39
2024 Research $14,745 11
2023 General $59,646 36
2023 Research $11,079 12
2022 General $35,613 32
2022 Research $19,108 18
2021 General $91,528 45
2021 Research $24,245 16
2020 General $60,777 25
2020 Research $28,339 33
2019 General $176,800 139
2019 Research $26,449 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amit Bar-Or
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Amit Bar-Or were reported at $70,818. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Amit Bar-Or Neurology median Middle half National median
2019 $176,800 $474 $118–$2,177 $163
2020 $60,777 $367 $82–$2,309 $114
2021 $91,528 $438 $104–$2,547 $132
2022 $35,613 $442 $103–$2,388 $149
2023 $59,646 $464 $119–$2,312 $160
2024 $100,696 $468 $119–$2,323 $164
2025 $70,818 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $128,635 60 payments
  2. F. Hoffmann-La Roche AG $102,851 64 payments
  3. EMD Serono, Inc. $58,390 45 payments
  4. Sanofi-Aventis U.S. LLC $48,637 12 payments
  5. Genentech, Inc. $43,820 45 payments
  6. Novartis Pharma AG $40,667 25 payments
  7. Sanofi US Services Inc. $32,047 9 payments
  8. Hoffmann-La Roche Limited $24,431 9 payments
  9. GlaxoSmithKline, LLC. $16,896 16 payments
  10. Biogen, Inc. $15,529 11 payments
  11. Other $83,975 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $428,540 145 payments
  2. Travel and Lodging $82,242 71 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $76,735 33 payments
  4. Food and Beverage $6,333 95 payments
  5. Education $2,027 3 payments
Products named General payments · program years 2019–2025
  1. OCREVUS $115,664 81 payments
  2. AUBAGIO $34,053 8 payments
  3. LEMTRADA $34,053 8 payments
  4. NO PRODUCT DISCUSSED $34,001 30 payments
  5. FTY720D_GILENYA_NEUROSCIENCE $16,039 7 payments
  6. KESIMPTA $12,342 6 payments
  7. ZEPOSIA $11,556 6 payments
  8. OMB157G_ARZERRA_HEMATOLOGY $8,571 7 payments
  9. Evobrutinib $6,550 1 payment
  10. COPAXONE $6,080 2 payments
  11. Other $30,192 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $88,488 80 payments
  2. Novartis Pharmaceuticals Corporation $44,896 45 payments
  3. Genzyme Corporation $7,072 15 payments
  4. Celgene Corporation $6,684 2 payments
  5. Novartis Pharma AG $2,403 2 payments
  6. Genentech, Inc. $1,350 1 payment

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$2,257

Medicare's payments for the services billed

Medicare patients

21

Average age 63

Services billed

37

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KESIMPTA
  • Novartis Pharma AG $9,116
$9,116 — —
OCREVUS
  • F. Hoffmann-La Roche AG $5,685
  • Genentech, Inc. $2,070
$7,755 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

492 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record